In vitro evaluation of the activity of imipenem-relebactam against 451 recent clinical isolates of Bacteroides group and related species

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 10, 2016, Pages 6393-6397

  Snydman, David R ^a   Jacobus, Nilda V ^a   McDermott, Laura A ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFOXITIN; CHLORAMPHENICOL; CLINDAMYCIN; DORIPENEM; ERTAPENEM; IMIPENEM; IMIPENEM PLUS RELEBACTAM; LINEZOLID; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; RELEBACTAM; SULTAMICILLIN; TIGECYCLINE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; AZABICYCLO DERIVATIVE; MK-7655;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; BACTEROIDES; BACTEROIDES CACAE; BACTEROIDES FRAGILIS; BACTEROIDES OVATUS; BACTEROIDES THETAIOTAOMICRON; BACTEROIDES UNIFORMIS; BACTEROIDES VULGATUS; CONTROLLED STUDY; DILUTION; EVALUATION STUDY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARABACTEROIDES DISTASONIS; PRIORITY JOURNAL; CLINICAL TRIAL; DRUG EFFECTS; DRUG POTENTIATION; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MULTICENTER STUDY;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTEROIDES; DRUG SYNERGISM; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS;

EID: 84992533316     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01125-16     Document Type: Article

References (10)

1. Hirsch EB, Ledesma KR, Chang K-T, Schwartz MS, Motyl MR, Tam VH. 2012. In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother 56:3753-3757. http://dx.doi.org/10.1128/AAC.05927-11.
2. Castanheira M, Mendes RE, Woosley LN, Jones RN. 2011. Trends in carbapenemase-producing E. coli and Klebsiella spp. from Europe and the Americas: report from SENTRY antimicrobial surveillance programme (2007-09). J Antimicrob Chemother 66:1409-1411. http://dx.doi.org/10.1093/jac/dkr081.
3. Lucasti C, Vasile L, Sandesc D, Venskutonis D, McLeroth P, Chen K, Brown M, Losada M, Pedley A, Kartsonis N, Paschke A. 2015. A phase 2 study to evaluate the efficacy & safety of relebactam (REL) + imipenem/cilastatin (IMI) vs IMI alone in subjects with complicated intra-abdominal infection (cIAI), abstr F-269. Abstr Intersci Conf Antimicrob Agents Chemother, San Diego, CA, 17 to 21 September 2015.
4. Snydman DR, Jacobus NV, McDermott LA, Golan Y, Hecht DW, Goldstein EJC, Harrell L, Jenkins S, Newton D, Pierson C, Rihs J, Yu VL, Venezia R, Iannini P, Finegold SM, Gorbach SL. 2010. Lessons learned from the anaerobe survey: historical perspectives and review of the most recent data (2005-2007). Clin Infect Dis 50(Suppl 1):S26-S33. http://dx.doi.org/10.1086/647940.
5. Snydman DR, Jacobus NV, McDermott LA, Ruthazer R, Golan Y, Goldstein EJC, Finegold SM, Harrell LJ, Hecht DW, Jenkins SG, Pierson C, Venezia R, Yu VL, Rihs J, Gorbach SL. 2007. National survey on the susceptibility of B. fragilis group: report and analysis of trends from 1997-2004 in the United States. Antimicrob Agents Chemother 51:1649-1655. http://dx.doi.org/10.1128/AAC.01435-06.
6. Snydman DR, Jacobus NV, McDermott LA, Golan Y, Goldstein EJC, Harrell LJ, Jenkins SG, Newton D, Pierson C, Rosenblatt J, Venezia R, Gorbach SL, Queenan AM, Hecht DW. 2011. Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009. Anaerobe 17:147-151. http://dx.doi.org/10.1016/j.anaerobe.2011.05.014.
7. Jousmine-Somer HR, Summanen P, Citron DM, Baron EJ, Wexler HM, Finegold SM. 2002. Wadsworth-KTL anaerobic bacteriology manual, 6th ed. Star Publishing Co. Belmont, CA.
8. Clinical and Laboratory Standards Institute. 2012. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard. CLSI document M11-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing: 19th informational supplement. CLSI document M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Pfizer, Inc. 2015. Tygacil: tigecycline for injection. Sterile, lyophilized powder for intravenous use. 50 mg/vial. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/021821s021lbl.pdf.